Company Overview

Pipeline

Nabriva’s lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria. Extensive Phase I data have demonstrated that BC-3781 can achieve therapeutically relevant blood and tissue levels in man with excellent tolerability when administered by either oral or intravenous routes. Recent Phase II data have further demonstrated that BC-3781 has efficacy comparable to the gold standard, Vancomycin, and that it has a good safety profile in patients treated for serious skin infections. 

Based on these results Nabriva has now successfully achieved proof-of-concept for the systemic use of pleuromutilin antibiotics in man to treat ABSSSI, community-acquired bacterial pneumonia (CABP) and other indications. 

View detailed Pipeline

© Nabriva Therapeutics Forschungs GmbH

News

18.7.2012
Nabriva Therapeutics Announces Management Changes
01.06.2012
Forest Laboratories and Nabriva Therapeutics sign Agreement
15.09.2011
Extended Phase II Results for BC-3781
18.04.2011
Positive Results from Phase II Trial
10.01.2011
Completed recruitment of Phase II clinical trial BC-3781
10.09.2010
BC-3781 Shows Therapeutic Potential
02.06.2010
Phase II of pleuromutilin antibiotic BC-3781
31.05.2010
Nabriva nominated as a finalist for the 2010 Red Herring 100 Europe Award
12.04.2010
Nabriva reports successful Phase I clinical trial for BC-3781
28.10.2009
Nabriva Therapeutics raises Euro 15 Million (USD 22 Million)
23.07.2009
Nabriva Therapeutics initiates Clinical Phase I trial of pleuromutilin antibiotic BC-3781
07.05.2009
Nabriva Therapeutics Appoints New Supervisory Board Member
27.03.2009
Nabriva Therapeutics Appoints Dr. David Chiswell as Chief Executive Officer
19.01.2009
Nabriva Therapeutics Appoints Chief Medical Officer
PRESS RELEASE ARCHIVE
See Nabriva at the following conferences
Corporate Factsheet